US › Healthcare

vTv Therapeutics Inc (VTVT)

US · Healthcare · Biotechnology

$31.40+3.09%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-13.1M

EPS

$-1.05

EPS estimate

$-0.75

EPS came in at -1.05 against a street estimate of -0.75 — a miss of 40.0%.

Key statistics

Market cap

$120.4M

Forward P/E

0.0

P/B

1.59

Book value

$6.34

EPS (TTM)

$-0.75

52-week high

$44.00

52-week low

$19.50

50-day MA

$32.57

200-day MA

$34.43

Beta

0.28

Analyst view

Analysts rate vTv Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $54.71.

Shareholding

Insiders

38.83%

Institutions

40.75%

Largest institutional holders

Fund	Stake
Samsara BioCapital, LLC	7.55%
Millennium Management LLC	6.83%
FMR Inc	6.59%
Siren, L.L.C.	4.12%
Baker Bros Advisors LP	3.75%
Vanguard Capital Management, LLC	2.75%
Trails Edge Capital Partners, LP	2.15%
Aisling Capital Management LP	1.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for vTv Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.